Takeda

Takeda Pharmaceutical Co. will buy U.S.-based Inviragen Inc. for an initial $35 million (about 3.5 billion yen) and future payments of up to $215 million linked to clinical...

OSAKA—Takeda America Holdings Inc., a subsidiary of Takeda Pharmaceutical Co., is to buy LigoCyte Pharmaceuticals Inc. in a deal that includes an upfront payment of $60...

Takeda Pharmaceutical Co. announced Aug. 3 it has signed an agreement with Johnson & Johnson for the exclusive distribution rights in Japan of seven over-the-counter drugs...

OSAKA and CAMBRIDGE, Mass. – Takeda Pharmaceutical Co. and Millennium: The Takeda Oncology Co., announced July 22 that the Committee for Medicinal Products for Human Use...

Takeda Pharmaceutical Co. and AMAG Pharmaceuticals Inc. announced June 25 the granting of marketing authorization by the European Commission for ferumoxytol, a new intravenous...

Takeda Pharmaceutical Co. and Pfizer Japan Inc. announced on June 18 that they have concluded an agreement in which Takeda will cease distribution of 13 of the 15 Pfizer...

Takeda Pharmaceutical Co. announced Feb. 7 that Edarbyclor (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of...

-- First and only fixed-dose combination medication in the U.S. to combine an angiotensin II receptor blocker with the diuretic chlorthalidone --

Takeda Pharmaceutical Co. announced Dec. 9 that the European Commission has granted marketing authorization for Edarbi, a new once-daily angiotensin receptor blocker for the...